Navigation Links
UGA animal vaccine may slow deadly spread of Chagas disease
Date:2/16/2012

Athens, Ga. Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global travel increases, it's becoming a greater threat in the United States and Europe as well.

Chagas, which is caused by the parasite Trypanosoma cruzi, or T. cruzi, is the leading cause of death among young-to-middle-age adults in endemic areas of South America, and many people live years without symptoms while their hearts and digestive systems suffer irreparable damage.

Now, thanks in part to a five-year, $1.8 million grant from the National Institutes of Health, University of Georgia researcher Rick Tarleton is close to developing the first vaccine for pets that will ultimately prevent the spread of disease to humans.

"One of the problems with T. cruzi is that it infects not just humans but many different animals," said Tarleton, Distinguished Research Professor in the department of cellular biology and member of the UGA Center for Tropical and Emerging Global Diseases. "What that means is that it will never be eradicated; you can't kill or vaccinate all the animals that carry this parasite," he said.

T. cruzi is most often spread via a subspecies of blood-feeding insects called triatomines. These insects, commonly known as "kissing bugs" because they tend to bite people on the face and lips, feed and defecate on human skin. Triatomine feces containing the parasite are then rubbed into the bite when humans scratch the wound or when humans rub their eyes or mouth.

While kissing bugs are ultimately responsible for passing the disease on to humans, the bugs that live in people's homes don't normally carry the disease. The bugs become infected when they bite the family pet.

"Humans end up being incidental hosts for this parasite," Tarleton said. "It really circulates much better and at much higher levels in a lot of other animal species."

Dogs, cats, goats or any other animal living in or around homes are likely to become infected from kissing bugs living in shrubs, woods, kennels or barns. These animals then expose kissing bugs already nesting in homes to the T. cruzi parasite. Once the insects in a home carry the parasite, the chances of human infection increase significantly.

It is estimated there are 300,000 people in the U.S. infected with T. cruzi, and studies show a sizeable number of dogs, particularly in the southern U.S., are infected as well, according to Tarleton.

While most Americans do not live in houses where kissing bugs thrive, the bugs are commonplace in the southern U.S., and they are capable of spreading the disease to humans. Transmission of the disease to humans may also occur through blood transfusions and organ transplants.

Tarleton's vaccine uses a live parasite that has been genetically modified so that it is incapable of replicating inside the host.

"We have a parasite that can grow in the insect and can infect an animal, but when it goes inside a cell, it cannot replicate," Tarleton said. "As a result, the immune system controls that infection, but you also get induction of a nice, strong immune response, which is what you need a vaccine to do."

Successful implementation of this vaccine could improve the lives of millions of people in Central and South America, but it would also help prevent the spread of the disease here in the U.S.

Immunology has given us vaccines for humans that have effectively rid the U.S. of diseases like polio and small pox, but because T. cruzi affects so many animals, Tarleton is certain that it will always be with us.

While Tarleton is frustrated that the science does not exist to create a human vaccine, he is confident that using immunological techniques on animals will significantly reduce the number of human infections.


'/>"/>

Contact: Rick Tarleton
tarleton@uga.edu
706-542-3378
University of Georgia
Source:Eurekalert

Related biology news :

1. AZTI-Tecnalia researches the use of vegetable by-products for animal feed
2. New tech removes air pollutants, may reduce energy use in animal ag facilities
3. A new method for testing allergenic substances without experimental animals
4. Archaeologists find new evidence of animals being introduced to prehistoric Caribbean
5. Mutants with heterozygote disadvantage can prevent spread of transgenic animals
6. New model more accurately describes migratory animals extinction risk
7. Animal study suggests that newborn period may be crucial time to prevent later diabetes
8. Progeria: Promising results from new gene therapy on animals
9. WSU researchers demonstrate rare animal model for studying depression
10. Poisonous oceans delayed animal evolution
11. Dont panic: The animals guide to hitchhiking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
Breaking Biology Technology: